Transgene Investor Relations Material
Latest events
Status Update
Transgene
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Transgene SA
Access all reports
Transgene SA is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company's core expertise lies in the design and development of therapeutic vaccines and oncolytic viruses. Transgene leverages advanced viral vector technology to create targeted treatments that aim to induce immune responses against cancer cells, either by directly attacking them or by enhancing the body's immune system to do so. Key products in its clinical-stage pipeline include TG4050, an individualized therapeutic vaccine developed using the myvac platform, and TG4001, aimed at treating HPV-positive cancers. The company also develops oncolytic viruses like BT-001 and TG6050 under its Invir.IO platform. The company is headquartered in Illkirch-Graffenstaden, France, and its shares are listed on the Euronext Paris.
Key slides for Transgene SA
H1 2024
Transgene SA
H2 2024
Transgene SA
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
TNG
Country
🇫🇷 France